Epoetin alfa use in patients with ESRD: An analysis of recent US prescribing patterns and hemoglobin outcomes

American Journal of Kidney Diseases

Volumn 46, Issue 3, 2005, Pages 481-488

  Collins, Allan J ^b   Brenner, Robert M ^b   Ofman, Joshua J ^b   Chi, Eric M ^b   Stuccio White, Nina ^b   Krishnan, Mahesh ^b   Solid, Craig ^b   Ofsthun, Norma J ^b   Lazarus, J Michael ^a  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

^b NONE

Author keywords

Anemia; End stage renal disease (ESRD); Epoetin alfa; Erythropoietin; Hemodialysis (HD); Hemoglobin; Medicare; Reimbursement

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG DOSE REDUCTION; EVALUATION; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY FAILURE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDICARE; PRACTICE GUIDELINE; PRESCRIPTION; RETROSPECTIVE STUDY; TITRIMETRY; TREATMENT OUTCOME; UNITED STATES;

ANEMIA; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG UTILIZATION; EPOETIN ALFA; GUIDELINE ADHERENCE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 23944511399     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2005.05.018     Document Type: Article

References (33)

1. B.C. Astor, P. Muntner, A. Levin, J.A. Eusatce, J. Coresh Association of kidney function with anemia The Third National Health and Nutrition Examination Survey (1988-1994) Arch Intern Med 162 2002 1401 1408
2. National Kidney Foundation K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease Evaluation, classification, and stratification Am J Kidney Dis 39 suppl 1 2002 S1 S266
3. A. Levin, C.R. Thompson, J. Ethier Left ventricular mass index in early renal disease Impact of decline in hemoglobin Am J Kidney Dis 34 1999 125 134
4. US Renal Data System USRDS 2004 Annual Data Report 2004 The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
5. K.M. Braumann, B. Nonnast-Daniel, D. Böning, A. Böcker, U. Frei Improved physical performance after treatment of renal anemia with recombinant human erythropoietin Nephron 58 1991 129 134
6. J.H. Horina, G. Schwaberger, H. Brussee, G. Sauseng-Fellegger, H. Holzer, G.J. Krejs Increased red cell 2,3-diphosphoglycerate levels in haemodialysis patients treated with erythropoietin Nephrol Dial Transplant 8 1993 1219 1222
7. H.T. Robertson, N.R. Haley, M. Guthrie, D. Cardenas, J.W. Eschbach, J.W. Adamson Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients Am J Kidney Dis 15 1990 325 332
8. J.T. Marsh, W.S. Brown, D. Wolcott rHuEPO treatment improves brain and cognitive function of anemic dialysis patients Kidney Int 39 1991 155 163
9. J.D. Harnett, P.S. Parfrey Cardiac disease in uremia Semin Nephrol 14 1994 245 252
10. I.C. Macdougall, N.P. Lewis, M.J. Saunders Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin Lancet 335 1990 489 493
11. J. Pascual, J.L. Teruel, J.L. Moya, F. Liaño, M. Jiménez-Mena, J. Ortuño Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis A prospective study Clin Nephrol 35 1991 280 287
12. V. Wizemann, R. Schäfer, W. Kramer Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy Nephron 64 1993 202 206
13. A.J. Collins, S. Li, W. St Peter Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36% to 39% J Am Soc Nephrol 12 2001 2465 2473
14. J.Z. Ma, J. Ebben, H. Xia, A.J. Collins Hematocrit level and associated mortality in hemodialysis patients J Am Soc Nephrol 10 1999 610 619
15. N. Ofsthun, J. LaBrecque, E. Lacson, M. Keen, J.M. Lazarus The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients Kidney Int 63 2003 1908 1914
16. H. Xia, J. Ebben, J.Z. Ma, A.J. Collins Hematocrit levels and hospitalization risks in hemodialysis patients J Am Soc Nephrol 10 1999 1309 1316
17. R.W. Evans, B. Rader, D.L. Manninen The quality of life of hemodialysis recipients treated with recombinant human erythropoietin JAMA 263 1990 825 830
18. H. Furuland, T. Linde, J. Ahlmén, A. Christensson, U. Strömbom, B.G. Danielson A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients Nephrol Dial Transplant 18 2003 353 361
19. N. Muirhead, A. Laupacis, C. Wong Erythropoietin for anaemia in haemodialysis patients Results of a maintenance study Nephrol Dial Transplant 7 1992 811 816
20. J.W. Eschbach, M.H. Abdulhadi, J.K. Browne Recombinant human erythropoietin in anemic patients with end-stage renal disease Ann Intern Med 111 1989 992 1000
21. R.L. Pisoni, J.L. Bragg-Gresham, E.W. Young Anemia management outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS) Am J Kidney Dis 44 2004 94 111
22. National Kidney Foundation K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease Update 2000 Am J Kidney Dis 37 suppl 1 2001 S182 S238
23. Centers for Medicare and Medicaid Services 2003 Annual Report, End Stage Renal Disease Clinical Performance Measures Project 2003 Department of Health and Human Services, Centers for Medicare and Medicaid Services, Center for Beneficiary Choices Baltimore, MD
24. A.J. Collins, T.L. Roberts, W.L. St Peter, S.-C. Chen, J. Ebben, E. Constantini United States Renal Data System assessment of the impact of the National Kidney Foundation-Dialysis Outcomes Quality Initiative guidelines Am J Kidney Dis 39 2002 784 795
25. US General Accounting Office: Dialysis Facilities: Problems Remain in Ensuring Compliance With Medicare Quality 2003 Washington, DC, October GAO-04-63:1-57
26. J.S. Berns, H. Elzein, R.I. Lynn, S. Fishbane, I.S. Meisels, P.B. DeOreo Hemoglobin variability in epoetin-treated hemodialysis patients Kidney Int 64 2003 1514 1521
27. J.B. Wish Can evidence drive the development of a sound national EPO reimbursement policy? Am J Kidney Dis 41 2003 254 258
28. E. Lacson, N. Ofsthun, J.M. Lazarus Effect of variability in anemia management on hemoglobin outcomes in ESRD Am J Kidney Dis 41 2003 111 124
29. D.N. Reddan, D.L. Frankenfield, P.S. Klassen Regional variability in anaemia management and haemoglobin in the US Nephrol Dial Transplant 18 2003 147 152
30. K.-U. Eckardt Anaemia of critical illness - Implications for understanding and treating rHuEPO resistance Nephrol Dial Transplant 17 suppl 5 2002 S48 S55
31. I.C. Macdougall, A.C. Cooper Erythropoietin resistance The role of inflammation and pro-inflammatory cytokines Nephrol Dial Transplant 17 suppl 11 2002 S39 S43
32. R.L. Pisoni, E.W. Young, D.M. Dykstra Vascular access use in Europe and the United States Results from the DOPPS Kidney Int 61 2002 305 316
33. R.N. Greenwood, C. Ronco, F. Gastaldon Erythropoietin dose variation in different countries and its relationship to drug resistance Kidney Int Suppl 87 2003 S78 S86